Furthermore, a combination of three biomarkers (NfL with p-tau181, plus either GFAP or the Aβ42/40 ratio) achieved a discriminative power of 0.89–0.90 between AD and FTD. This evidence concerns the gene NEFL and Alzheimer disease.